Thombocytopenia (T) in patients with chronic hepatitis C: management with interleukin-11 (IL11)

Rangaraj, Venkat; Mendenhall, Charles; Goldberg, Stephen
September 2003
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS82
Academic Journal
An abstract of the article "Thombocytopenia (T) in Patients With Chronic Hepatitis C: Management With Interleukin-11 (IL11)," by Venkat Rangaraj, Charles Mendenhall and Goldberg Stephen is presented.


Related Articles

  • Peginterferon-α-2b.  // Reactions Weekly;5/21/2011, Issue 1352, p30 

    The article describes the case of a 28-year-old man who developed thrombocytopenia during treatment with peginterferon-α-2b for chronic hepatitis C.

  • Peginterferon.  // Reactions Weekly;8/14/2010, Issue 1314, p34 

    The article describes the case of a 37-year-old woman who experienced severe thrombocytopenia while receiving peginterferon for chronic hepatitis C.

  • Hepatitis C increased risk for immune thrombocytopenic purpura. Jacob, Harry S. // Hem/Onc Today;3/25/2009, Vol. 10 Issue 6, p6 

    The article discusses a study," published in a 2009 issue of "Archives of Internal Medicine," which examined the risk for developing immune thrombocytopenic purpura in patients with hepatitis C.

  • Peginterferon/ribavirin.  // Reactions Weekly;9/22/2007, Issue 1170, p27 

    The article describes two cases of patients who developed thrombocytopenia while receiving peginterferon and ribavirin for chronic hepatitis C. The patients developed severe thrombocytopenia after receiving peginterferon and ribavirin. The platelet counts of both patients decreased after taking...

  • Extrahepatic manifestations associated with chronic hepatitis C infections in Poland. D. A., Zarebska-Michaluk; D. M., Lebensztejn; W. M., Kryczka; E., Skiba // Advances in Medical Sciences (De Gruyter Open);2010, Vol. 55 Issue 1, p67 

    Purpose: To assess the prevalence and predictive factors of extrahepatic manifestation (EM) in patients with chronic hepatitis C (CHC) infection in Poland. Material and Methods: 340 consecutive patients (mean age: 42 years) with untreated CHC were studied between 2000 and 2006. The HCV infection...

  • Erythropoietin Treatment Is Associated with More Severe Thrombocytopenia in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy. Homoncik, Monika; Sieghart, Wolfgang; Formann, Elisabeth; Schmid, Monika; Ferenci, Peter; Gangl, Alfred; Jilma, Bernd; Peck-Radosavljevic, Markus // American Journal of Gastroenterology;Oct2006, Vol. 101 Issue 10, p2275 

    BACKGROUND: Erythropoietin (EPO) not only stimulates erythropoiesis but also thrombopoiesis. As pegylated-interferon-α(PEG-IFN-α)-induced thrombocytopenia may become a limiting factor for continuation of therapy, the present study investigated if EPO can alleviate PEG-IFN-α induced...

  • PEG interferon-α-2a/ribavirin.  // Reactions Weekly;3/20/2004, Issue 993, p11 

    Discusses research being done on the association of possible autoimmune thrombocytopenia with pegylated interferon-alpha-2a plus ribavirin treatment for hepatitis C. Reference to a study by B. C. Medeiros et al published in a January 2004 issue of the "Journal of Clinical Gastroenterology";...

  • Multiple drugs.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p203 

    An abstract of the article "Eltrombopag : How secure in triple therapy of HCV ?" by Y. Kayar and others is presented.

  • The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia. Danish, Fazal-i-Akbar; Yasmin, Saeeda // Hepatic Medicine: Evidence & Research;2013, Vol. 5, p17 

    Eltrombopag is a 2nd generation thrombopoietin-receptor agonist. It binds with the thrombopoietin-receptors found on the surfaces of the megakaryocytes & increases platelet production. Many recent studies have suggested a potential role for this novel agent in the treatment of thrombocytopenia...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics